Hypertrophy

CREATV BIO PRESENTS CANCER SCREENING AND CANCER DIAGNOSTICS DATA AT 1ST INTERNATIONAL CONFERENCE ON POLYPLOID GIANT CANCER CELLS

Retrieved on: 
Martedì, Aprile 30, 2024
Giant, Cancer, Prognosis, Lung cancer, Monroe Dunaway Anderson, Conference, PD-L1, University, Patient, Biology, MD Anderson Cancer Center, Hypertrophy, Biomarker, Medical imaging

HOUSTON, April 30, 2024 /PRNewswire/ -- Creatv Bio, A Division of Creatv MicroTech, Inc. (Creatv), ( https://creatvbio.com/ ) and collaborators were invited to present clinical data from Creatv's blood test for cancer screening and diagnostics at the 1st International Conference on Polyploid Giant Cancer Cells: Biology and Clinical Applications – held February 16 and 17 at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Key Points: 
  • HOUSTON, April 30, 2024 /PRNewswire/ -- Creatv Bio, A Division of Creatv MicroTech, Inc. (Creatv), ( https://creatvbio.com/ ) and collaborators were invited to present clinical data from Creatv's blood test for cancer screening and diagnostics at the 1st International Conference on Polyploid Giant Cancer Cells: Biology and Clinical Applications – held February 16 and 17 at The University of Texas MD Anderson Cancer Center in Houston, Texas.
  • This conference brought together for the first-time international researchers and clinicians to discuss the biology and clinical applications of Polyploid Giant Cancer Cells (PGCCs) and the role they may play in cancer.
  • The Conference featured 28 presentations on PGCCs and more than a dozen posters.
  • "These results are quite encouraging and give clinicians another tool to help guide their treatment of cancer patients."

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

Retrieved on: 
Mercoledì, Aprile 24, 2024
Heart, Blood, European Patent Convention, Hypertrophy, ECG, HSCS, Intelligence, Environment, Patent, Patient, Death, Cardiovascular disease, Growth, Medical device

Diastolic dysfunction (impaired cardiac relaxation) is a sensitive and crucial indicator of overall heart health, providing one of the earliest signs of heart disease, with onset typically occurring before symptoms.

Key Points: 
  • Diastolic dysfunction (impaired cardiac relaxation) is a sensitive and crucial indicator of overall heart health, providing one of the earliest signs of heart disease, with onset typically occurring before symptoms.
  • Diastolic dysfunction is caused by all common issues that affect heart function or that produce hypertrophy.
  • Today, measures of diastolic function of the heart need to be assessed in a specialist cardiology environment, typically using echocardiography-based imaging.
  • The United States Patent and Trademark Office has issued eight utility patents and one design patent to HeartSciences, with patent expiration dates ranging from March 2031 through August 2040.

3DLOOK, the leader in AI-powered mobile body scanning, launches FitXpress -- the first comprehensive fitness monitoring and predictive body modeling solution

Retrieved on: 
Mercoledì, Aprile 10, 2024
Frustration, Hypertrophy, Weight gain, Body mass index, AI, BMR, Electricity, Health, BMI, IEEE, Weight loss, Research, 3D, API, Exercise, Electronics, Acquisition, Medical imaging

NEW YORK, April 10, 2024 /PRNewswire-PRWeb/ -- 3DLOOK, the global leader in AI-powered mobile body scanning solutions, has announced the launch of FitXpress — the first AI-powered body scanning, health data monitoring, and progress visualization solution for health and fitness businesses. Through a single API, customers can access precise AI-powered body scanning, 3D body models, fat percentage, body mass index (BMI), and basal metabolic rate (BMR) estimates, target weight visualizations, and highly-accurate progress tracking.

Key Points: 
  • NEW YORK, April 10, 2024 /PRNewswire-PRWeb/ -- 3DLOOK , the global leader in AI-powered mobile body scanning solutions, has announced the launch of FitXpress — the first AI-powered body scanning, health data monitoring, and progress visualization solution for health and fitness businesses.
  • Considering the potential 30% discrepancy in traditional scales and the inaccuracies of even the most advanced body-fat scales, the issue becomes clear.
  • Certified as a standard in mobile body scanning by IEEE (Institute of Electrical and Electronics Engineers), the technology delivers unmatched industry-leading accuracy.
  • FitXpress is available now via API, providing seamless integration with any mobile or web application.

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Retrieved on: 
Martedì, Aprile 2, 2024
Hypertrophy, Heart, CRDL, Patient, Mayo Clinic, PPAR, Agent handling, Cleveland Clinic, Fibrosis, European, Therapy, Myocarditis, Analysis, American Heart Association, Human, Massachusetts General Hospital, Pericarditis, MMT, Heart failure, American College, Safety, ODD, Cardiology, Clinical professor, Disease, Pericardium, Research, World Heart Federation, Management, University, Death, Pericardial effusion, Maverick, Reactive oxygen species, TSX, Priority review, FDA, Conversation, Financial statement, Inflammation, Fast Track, Calcium, Wound healing, API, Pharmaceutical industry

"Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.

Key Points: 
  • "Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.
  • In January 2023, Cardiol announced the first patient had been enrolled in the Company's Phase II open-label pilot study ("MAvERIC-Pilot") investigating the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis.
  • In November 2023, Cardiol announced that it had exceeded 50% of the patient enrollment target for the MAvERIC-Pilot study.
  • In January 2024, Cardiol announced that ARCHER had exceeded 50% patient enrollment and was progressing ahead of the original study timeline.

Viz.ai® Announces Three New Studies Supporting Viz HCM™ Module for the Detection and Management of Suspected Hypertrophic Cardiomyopathy

Retrieved on: 
Mercoledì, Aprile 3, 2024
Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, Cardiology, Deep learning, FACC, Harvard Medical School, Machine learning, Cone Health Women's Hospital, PPV, Innovation, Algorithm, Artificiality, Assistant, Disease, Associate, Patient, Atlantic Health System, Triage, Salem Hospital, AI, Viz, American College, Massachusetts General Hospital, HCM, Hospital, Hypertrophic cardiomyopathy, Senior counsel, Sports cardiology, Hypertrophy, Medical director, Probability, FDA, ACC, ECG, Mass, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care.
  • The Viz HCM module is the first and only AI algorithm cleared by the FDA for HCM.
  • The study found that Viz HCM performance in suspected HCM detection was consistent across various racial backgrounds with a sensitivity of 68.4% and specificity of 99.1%.
  • This validates the effectiveness of relevance score sorting for prioritizing higher probability HCM-positive patients identified by deep-learning algorithms analyzing ECG data.

Stealth BioTherapeutics Presents Data of Novel Compound, SBT-589, in Friedreich's Ataxia Cardiac Models at the Wellcome Trust Mitochondrial Medicine Conference

Retrieved on: 
Martedì, Marzo 19, 2024
Discovery, Friedreich's ataxia, Death, Hypertrophy, Conditional sentence, Conference, Disease, Mitochondrion, The Company, Mouse, Mortality, Cardiomyopathy, Senior, Heart failure, Mitochondrial disease, Pathology, Stealth, Pharmaceutical industry

NEEDHAM, Mass., March 19, 2024 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new SBT-589 data demonstrating cardioprotective effects across pre-clinical models of Friedreich's ataxia (FA). The data were presented at the Wellcome Trust Conference on Mitochondrial Medicine – Therapeutic Development, held March 18-20, 2024, in Cambridge, England.

Key Points: 
  • The data were presented at the Wellcome Trust Conference on Mitochondrial Medicine – Therapeutic Development, held March 18-20, 2024, in Cambridge, England.
  • SBT-589 is a promising novel molecule that acts on mitochondrial pathways essential for cellular health and energy production that are impaired in FA cardiomyopathy.
  • "Mitigating heart disease in FA is central to Stealth's ongoing efforts to improve the lives of individuals with FA.
  • The data were presented by Dr. Laura E. Kropp, Senior Manager of Discovery Biology at Stealth, and recipient of the Keith Michael Andrus Cardiac Award from the Friedreich's Ataxia Research Alliance.

Natural Farm Introduces Traditional Himalayan Yak Cheese: Handcrafted with Care

Retrieved on: 
Lunedì, Marzo 18, 2024
Amazon, Lactose, Calcium, Milk, Hypertrophy, Plaque, Dog, Allergy, CMO, Animal husbandry

ATLANTA, March 18, 2024 /PRNewswire-PRWeb/ -- Natural Farm, a leading provider of 100% all-natural dog treats, chews, and bones, launched an innovative new product line in February 2024. Yak Cheese Chews are crafted from pure yak and cow milk, using traditional methods that have been passed down through generations.

Key Points: 
  • Natural Farm is delighted to announce the launch of its latest product line within the allergen-friendly category, Himalayan Yak Cheese Chews.
  • Natural Farm is committed to producing innovative, healthy dog treats, and this new product line is a testament to their excellence in the pet products industry.
  • Yak Cheese Chews are crafted from pure yak and cow milk, using traditional methods that have been passed down through generations.
  • For more information on Natural Farm and their Yak Cheese Chews, please visit naturalfarmpet.com or email [email protected] .

BLACK SKULL LAUNCHES AT A FAIR IN CALIFORNIA A POST-WORKOUT WITH EXCLUSIVE SALE ON AMAZON

Retrieved on: 
Venerdì, Marzo 15, 2024
Health, GROW, Stevia, University, Hormone, Islam, Sport, Amazon, Lactose, Antibody, GMO, Colostrum, GDS, Hypertrophy, Quality of life, Jews, Diet, Investment, Water, Oligosaccharide, WHEY, Multimedia, BLACK, Soil, Food safety, Chocolate, Allergen, Dairy

SÃO PAULO, March 14, 2024 /PRNewswire/ -- BLACK SKULL (www.blackskullusa.com), a brand from Grow Dietary Supplements Labs USA (GDS), a leader in the hardcore nutrition segment in Brazil, participates in the largest fair in the world in the natural sector, the Natural Products Expo West, which takes place from March 12th to 16th, in Anaheim, California – USA. The brand will present its newest launch, WHEY GRASS FED, the first post-workout supplement that has 19g of high biological value protein and 1g of Bovine Colostrum, which will be sold exclusively on the AMAZON platform, initially for the North American market.

Key Points: 
  • The supplement is Halal and Kosher certified and will be presented at Natural Products Expo West.
  • Colostrum is composed of a powerful combination of bioactives (immunoglobulins, immune modulators and oligosaccharides), which support immunological, respiratory and intestinal health.
  • The product arrives in sustainable 900-gram packaging, with freeze-dried natural smell from the Amazon, such as Guaraná with Açaí and Chocolate with Cupuaçu.
  • "In addition to contributing to the health of consumers, WHEY GRASS FED will help fruit producer cooperatives in the Amazon and riverside families.

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Lunedì, Marzo 11, 2024
Fast Track, Cohort, Research, Orphan drug, FDA, Cardiovascular disease, Treatment, Clinical trial, Exercise, FTD, ODD, Phenotype, Patient, Public expenditure, Hypertrophy, FXN, Heart, Cadaver, G&A, Development, FA, Pharmaceutical industry

NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today reported fourth quarter and full year 2023 financial results and provided operational highlights.

Key Points: 
  • Data to date suggest that FA patients may have lower FXN levels in the heart versus peripheral tissues.
  • Across all three cardiac biopsies, we observed an increase in FXN levels as measured by liquid chromatography mass spectrometry relative to pre-treatment baseline levels.
  • Lexeo anticipates the gross proceeds from the private placement to be approximately $95.0 million, before deducting any offering related expenses.
  • G&A expenses were $15.4 million for the year ended December 31, 2023, compared to $12.0 million for the same period in 2022.

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Retrieved on: 
Lunedì, Febbraio 26, 2024
SAN, Metabolism, Inflammation, Food, HDAC6, HDAC, Exercise, Tubulin, Heart failure, Safety, Therapy, Acetylation, Patient, Hypertrophy, Fibrosis, SGLT2, MTAC, Oxidative stress, Nature Communications, Heart, HFD, Plasma, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publication of preclinical research related to Tenaya’s small molecule inhibitors of histone deacetylase 6 (HDAC6), including TN-301, in the February 26, 2024, issue of Nature Communications. The article, titled “Targeting HDAC6 to Treat Heart Failure with Preserved Ejection Fraction in Mice,” details the potential of inhibiting HDAC6 for the treatment of Heart failure with preserved ejection fraction (HFpEF), a form of heart failure that effects more than three million people in the U.S. alone1.

Key Points: 
  • The article, titled “Targeting HDAC6 to Treat Heart Failure with Preserved Ejection Fraction in Mice,” details the potential of inhibiting HDAC6 for the treatment of Heart failure with preserved ejection fraction (HFpEF), a form of heart failure that effects more than three million people in the U.S. alone1.
  • Tenaya’s highly selective small molecule inhibitors of the enzyme HDAC6 were discovered using the company’s modality-agnostic target discovery and validation capabilities.
  • For preclinical studies, Tenaya researchers used TYA-018, an HDAC6 inhibitor structurally and functionally similar to the company’s clinical candidate, TN-301.
  • The selective effects of HDAC6 inhibition were reaffirmed through genetic deletion studies, in which treatment of Hdac6 knockout mice did not display any of the beneficial effects that wild-type HFpEF mice did following treatment.